Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
- Ruben Minski's transition to Executive Chairman reflects thoughtful succession planning
- Jose Antonio Vieira brings over 30 years of experience in the pharmaceutical market
- Procaps' commitment to sustained success and dedication to delivering value to shareholders
- None.
After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps’ growth and success, transforming it into a global leader in pharmaceutical innovation. Under his guidance, Procaps has achieved numerous milestones, and positively impacting countless lives.
The Board of Directors expresses its deep gratitude to Ruben Minski for his unwavering commitment and outstanding leadership throughout the years. The decision to transition to the role of Executive Chairman reflects a thoughtful and deliberate succession planning process, as previously announced in February this year.
“It has been a privilege to serve as CEO of Procaps for the past 45 years. I look forward to focusing only on my role as Executive Chairman of the Board, where I can continue to contribute to the company´s strategic direction,” said Ruben Minski.
In his role as Executive Chairman of the Board, Ruben Minski will continue to provide strategic guidance, drawing upon his wealth of experience and industry knowledge. This transition underscores Procaps’ commitment to sustained success and its dedication to delivering value to shareholders.
The Board welcomes Mr. Vieira to Procaps. José Antonio brings a wealth of experience in the international pharmaceutical industry, including
“I'm very pleased to have Mr. Vieira joining Procaps. His knowledge, experience and leadership will certainly help us move to our next development phase, as we continue to strengthen our operations and focus on profitability and growth,” said Ruben Minski, Executive Chairman of the Board of Directors.
Mr. Vieira has over 30 years of experience in the pharmaceutical market, having worked for companies such as Novartis, Abbvie and AstraZeneca in
Mr. Vieira holds a degree in Economics from Fundação Armando Alvares Penteado in
“I'm honored with this new challenge and I am eager to lead the next chapter of Procaps as CEO. Procaps is a unique company with tremendous potential. I am excited about the opportunity to lead this exceptional team and build upon the legacy of innovation and excellence established by Ruben. Together with the talented individuals at Procaps, we will continue to advance our mission of improving lives through pharmaceutical solutions,” said Jose Antonio Vieira.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the
For more information, visit www.procapsgroup.com or Procaps’ investor relations website investor.procapsgroup.com.
This press release includes “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include projections on Mr. Vieira’s expected future performance as well as the expected benefits to be achieved by the appointment of Mr. Vieira as chief executive officer, and there can be no assurance that any such projections or benefits underlying the appointment of Mr. Vieira as chief executive officer will be obtained. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks included under the header “Risk Factors” in Procaps’ annual report on Form 20-F filed with the SEC, as well as Procaps’ other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122109496/en/
Investor Contact:
Melissa Angelini
IR Director - Procaps Group
ir@procapsgroup.com
investor.procapsgroup.com
Source: Procaps Group
FAQ
Who is the new CEO of Procaps Group and when will the transition be effective?
What is Ruben Minski's new role in Procaps Group?
What are some of the achievements under Ruben Minski's leadership at Procaps Group?
What experience does Jose Antonio Vieira bring to Procaps Group?